Skip to main content

Insights for life sciences organizations

Read, watch or listen to these resources to learn how real-world data can help you innovate, grow and improve patients’ lives.

""

E-book

The power of using integrated data to understand drug performance

These real-world examples show how integrated data can help you improve medication adherence, track patient journeys, evaluate total cost of care and more.

Dig deeper into the evolving role of real-world evidence

Clinicogenomics linked data advances research

Clinicogenomics data can fuel all stages of development.

Four steps to an enterprise data strategy

Maximize data investments.

Is Your Real-World Data Research Ready?

Go behind the scenes of real-world data.

Insights

The 11 things life sciences leaders need to know

We identified 11 trends worth watching.

How race and ethnicity data can bridge the health equity gap

The life sciences industry needs robust real-world data. For that data to reflect real-world populations, you need race and ethnicity data.

Let's Talk: Conversations from Optum Life Sciences

Discover what’s on the minds of innovative life science leaders with thought -provoking insights and discussions.

Solve contract challenges for gene therapies

Gene therapies have the potential to be transformative, but there are hurdles to overcome for value-based contracts to become widespread.

Getting ahead of the mental health crisis

See how leaders are advancing data strategies, screenings and exploring ways to connect consumers to mental health support.

How VBC can work for manufacturers

Value-based contracts can present challenges that must be overcome to bring gene therapies to market.

PMSA Webinar: Avoiding common RWD pitfalls

Optum experts give a snapshot of commonly encountered pitfalls when using RWD and recommendations to help avoid them in this PMSA webinar.

4 ways small and emerging biopharma can harness RWD now

Small and emerging biopharma companies are already having an impact on the industry. Learn how RWD can enhance your ability to innovate.

Accelerate drug development with clinicogenomic RWE

Optum, Novartis and GuardantINFORM experts discuss the ever-increasing importance of clinicogenomic data during this Endpoints News webinar.

Watch: OLS Data Leaders at STAT Summit

Break down common missteps when using RWD and create practical strategies to overcome them.

Sleep treatment across the ages

Combining real-world data and primary research helps us better understand insomnia.

Optum Dynamic Assessment of Pregnancies and Infants

Assess the impact of medication use during pregnancy and the impact on infant health.

Demonstrating product value with integrated data

A special webinar hosted by MM&M demonstrates how integrated EHR and claims data offers a new foundation for demonstrating product value.

Optum, FDA collaborate on vaccine and biologic research

FDA reaches agreement with life sciences segment of Optum to provide data and expertise to evaluate and research biologics and vaccines.

Real-world data fills rare disease data gaps

Data removes the barriers to understanding rare disease.

Evolving clinical trials from paper to digital

Accelerate research through a digitized model.

Dynamic Assessment Of Pregnancies And Infants

We help answer questions about maternal and infant health.

The unifying power of integrated data

Read how the integration of EHR and claims data can change what we can collectively learn about outcomes.

Modernizing clinical trials with EHRs

Discover how Optum and three provider organizations leveraged EHR systems to modernize a clinical trial aimed at diabetes treatment.

Reflections on PCMA's recent Annual Meeting

Total cost of care and value-based arrangements between manufacturers and payers is top of mind of HEOR and Medical Affairs leaders.

When ‘Is it safe for me?’ changes to ‘Is it safe for us?’

Studying the impact of treatments on pregnancy and infants can help patients, providers and pharmaceutical companies make key decisions.

Monitoring COVID-19 vaccine safety

Discover insights from Dr. John Seeger’s recent participation at the Duke-Margolis Thirteenth Annual Sentinel Initiative Public Workshop.

New Data Dimensions In Life Sciences Research

Expanded research methods can address cost at the root level.

Curious case of costly complications

How can analytics help tell your cost and outcomes story?

Clinicogenomics: The next big leap in real-world data

Optum clinical genomics is positioned to shape a new generation of evidence that accelerates understanding of disease.

Realizing the full potential of clinicogenomics

Join Optum genomics experts as they discuss the progress being made to develop datasets that will aid in drug discovery and development.

The Curious Case of the Costly Complication

Optum helps a client prove product effectiveness

Real-world data centralized teams

Expanding the use of RWD requires expertise and leadership.

Four steps to a RWD enterprise strategy

Lou Brooks, SVP, Real-World Data and Analytics at Optum

Real Talk on Real-World Evidence: Practical Applications in 2021

Virtual fireside chat with Advisory Board and Optum Life Sciences leaders explores the expanded use and next wave of RWE applications

Pinpoint asthma, COPD and ACOS with EHR data

Optum study highlights clinical clues in asthma and COPD.

Take Bold Action & Maximize Impact

Take Bold Action & Maximize Impact

Reconcile your RWD expectations to maximize your investment

Understand how routine clinical practice impacts information captured in real-world data (RWD).

Case study: Improving SGLT2i therapy guideline adherence

Article that covers OLS and Boehringer Ingelheim collaboration to increase adherence for patients with diabetes and CVD.

RWD Pitfalls Part 1: Using the right tools to approach RWD

When working with real-world data, learn from the lessons of others to help maximize your own business return.

Clinicogenomics: new, linked data is advancing research

Rich, longitudinal clinicogenomics data can fuel all stages of drug development.

Maximize clinical trial enrollment

Use clinical and claims data to conduct patient finding.

Forward-thinking strategies for 2022

Explore this video series featuring insights for Life Sciences leaders, delivered by experts from across health care.

Understanding Market Shifts

Optum expertise provides competitive insights.

Clinicogenomics Enable Precision Drug Development | Optum

Pilot Program Lowers Cardiovascular Disease Risk

An innovative program involving patient awareness and provider outreach improves patient use of lipid-lowering therapies.

2023 trends shaping life sciences strategies

Life sciences market experts from Optum and Advisory Board offer their bold predictions and insights in 2023 for the industry.

Building public confidence with health data

See how the FDA and Optum use real-world evidence to monitor the safety and effectiveness of COVID-19 vaccines in our youngest populations.

Informing the FDA BEST Initiative

As a key FDA collaborator, Optum Epidemiology generates reproducible results that inform regulatory decisions for COVID-19 vaccines.

Four steps to an enterprise data strategy

Explore the steps for creating a real-world data strategy that helps life sciences companies to maximize their data investments.

Is Your Real-World Data Research Ready?

Real-world data can help evaluate the effectiveness of medications and therapies, which is why evaluation should be part of the investment.

Preparing for the future of life sciences

Life sciences leaders are thinking differently with data to support novel strategies.

Case study: Identifying patients at risk for a bone break

Optum Life Sciences experts used real-world data to assist in the testing of an algorithm designed to assess for osteoporosis risk.

Break down silos in clinical trial design with RWD and tools

Clinical trial protocol design and feasibility often occur in silos. Learn how to make the overall trial design process more effective.

The 6 trends shaping pharma strategies in 2024

Life sciences market experts from Optum and Advisory Board share perspectives on trends that will influence the future drug value chain.

Catalyze the use of RWE in the life sciences industry

Discover how using real-world evidence (RWE) in the life sciences industry can help catapult learning and drive impact for your company.

Clinicogenomics: advancing discovery and treatment

Watch Dr. Ashley Brenton, VP, real-world evidence and genomics, Optum Life Sciences, discuss patient journeys and cohort building.

An interview with Jamie Freedman, MD, PhD, and Shalini Mohan, MD

This interview about health equity and clinical trials is part of the "Let's talk" conversation series.

Interview with Jason Spangler on value assessment frameworks

This interview is part of the "Let's talk" conversation series.

Toward Outcomes-Based Payments

Learn from industry leaders about the push to generate evidence and demonstrate value for health care provider value.

An interview with Chris Boone, PhD on precision medicine

This interview is part of the "Let's talk" conversation series.

Connecting Patients to Clinical Trials in Community Care Settings

Learn how real-world data can increase access beyond traditional research sites.

Natural language processing (NLP) methods for RWD insights

NLP systems allow us to draw insights from billions of unstructured medical notes. Learn more about our NLP methodology in this white paper.

Webinar: Solving trial recruitment challenges with data

Learn from clinical trial leaders how you can address recruitment roadblocks by unlocking real-world data (RWD).

What if pragmatic trials were more practical?

Pragmatic trials look increasingly attractive to researchers, but they’re tough to execute. Learn how to simplify the process.

6 guiding steps for selecting a fit-for-purpose data set

Using RWD that are not fit for purpose can waste time and money. Review 6 simple steps to guide your research towards the right data.

Promoting patient access to gene therapies for rare disorders

Optum Life Sciences experts discuss value-based contracts at the 5th Annual Gene Therapy for Rare Disorders Conference.

What if providers’ clinical data were research-ready?

Providers collect data about patients every day. But what should they be considering — and doing — to put their clinical data to good use?

Novel data collection for a difficult-to-study condition

To build a more complete picture of the patient burden, the Optum HEOR team investigates patients’ experiences with their treatment journey.

Reassess the Inflation Reduction Act with evidence in mind

Cut through the noise of the Inflation Reduction Act of 2022 with key points aimed to help life sciences leaders leverage impactful data.

Life Sciences: Top stakeholder questions to consider

Ask your stakeholders what they need early on. Consider these top questions that patients, providers, payers and regulators are looking to answer.

Missing pieces in the patient journey puzzle

Clinicogenomic data, unstructured data and novel clinical trials solutions can all contribute to completing the view of the patient journey.

Reexamine the effect of the Inflation Reduction Act

Learn how to prepare for tough conversations and questions related to the Inflation Reduction Act’s health care policies with data and evidence.

Integrated RWD: the key to accelerating innovation

To maximize the value of clinical innovations, you need dimensional, robust data. Learn about leveraging integrated cost and clinical data.

Unlock clinical insights with NLP technology

Learn about natural language processing (NLP) challenges and opportunities in the real-world data (RWD) space from Optum® NLP experts.

Challenges and opportunities with clinicogenomic data

Genomic data linked to the longitudinal health record hold great insight. How should researchers think about and use these powerful data?

The value of clinical notes: Beyond the structured data field

What more is there to the patient story? Get deeper data insight into patient-clinician interactions with de-identified clinical notes.

10 years of innovation with the FDA — and more in store

Dr. John Seeger reflects on Optum contributions to the Sentinel Initiative and looks forward to the opportunities ahead.

What’s informing HEOR strategies in 2025? Insights from our experts

E-book: The foundational forces affecting pharma today and beyond

What are 3 key trends manufacturers should consider when planning for 2025? Advisory Board and Optum® Life Sciences experts share their insights in this e-book.